Date: 2013-04-22
Type of information: R&D agreement
Compound: kinase target programme HD-001
Company: Horizon Discovery (UK) AstraZeneca (UK)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
collaboration
Action mechanism:
Disease:
Details: * On April 22, 2013, Horizon Discovery and AstraZeneca have entered into an exclusive collaboration and license agreement to explore Horizon’s first-in-class kinase target programme, HD-001, as a means of developing novel therapies for multiple cancer types. The HD-001 program, currently in the early stages of drug discovery, has the potential to be developed into a treatment based on modulation of a novel kinase. This target has been shown to be mutated in a range of cancer types including colon and lung. Importantly, the target has also been shown to play a key role in K-Ras mutant tumours. K-Ras is mutated in up to 40% of all cancer types causing resistance to many of the available targeted therapeutics and as a result is associated with poor patient outcomes, which makes the development of molecular targeted therapies against the gene a significant unmet need.
Financial terms: Under the terms of the agreement, Horizon will receive undisclosed upfront and preclinical milestone payments, and are eligible for clinical and approval milestones totaling up to $75 million, as well as tiered royalties.
Latest news:
